🏢 官网IRALNYDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 10-15(美东日)仅日期·时区推断·⟳ 抓取 20:00:54回填·⚡ 决策 10-15 20:01:42·12.2 天前
Alnylam 宣布将于10月29日盘前公布2026年三季报并召开电话会（仅日程通知）
这是每季度例行的财报日期/电话会预告，不含业绩数字、指引调整或任何业务新事实，市场无法据此重定价；真正的催化在10月29日财报本身，应届时另行研判。
📄 原文ALNY↗ 原文
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Oct 15, 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therape…
不做 Alnylam Pharmaceuticals（ALNY.US）
纯财报日期/电话会日程公告，无收入、利润、指引或业务增量，方向中性、无edge；真正催化在2026-10-29盘前财报，届时再研判，不在此信号上交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Alnylam仅通知Q3财报将于10月29日盘前发布并召开电话会，属例行日程公告，无收入/指引等增量信息，方向中性，不构成可交易事件。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
关键理由
- 纯日程通知，没有任何可驱动股价的新增基本面事实。
主要风险
- 真正的波动来自10月29日实际财报与指引，本信号不提供方向；若据此提前押注等于无信息博弈。
先例如何影响了这次决策
对本次决策的影响:确认本例为例行程式通知，直接AVOID，待财报日再做事件研究。
方向:无先例可参照；财报日期公告本身不产生方向性收益，故不检索同类事件价格反应。
涨幅量级:不足以也无需校准幅度——本事件无交易。
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`alny q3 2026 earnings webcast announcement | alnylam third quarter 2026 financial results conference call october 29 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 1,837 字
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Oct 15, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc.
(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open.
Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at
www.alnylam.com/events
. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its
Alnylam 2030
strategy to accelerate innovation and scale impact to transform human health. For more information, please visit
www.alnylam.com
or follow Alnylam on
X
,
LinkedIn
,
Facebook
,
Instagram
, or
YouTube
.
Alnylam Pharmaceuticals, Inc.
Bo Piela
(Media)
508-308-9783
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
Oct 15, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc.
(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open.
Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at
www.alnylam.com/events
. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its
Alnylam 2030
strategy to accelerate innovation and scale impact to transform human health. For more information, please visit
www.alnylam.com
or follow Alnylam on
X
,
,
,
, or
YouTube
.
Alnylam Pharmaceuticals, Inc.
Bo Piela
(Media)
508-308-9783
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a6bae2901e· 2026-10-15 20:01 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前